Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 4.24
BCRX's Cash to Debt is ranked higher than
65% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. BCRX: 4.24 )
BCRX' s 10-Year Cash to Debt Range
Min: 0.94   Max: 11087.67
Current: 4.24

0.94
11087.67
Equity to Asset 0.61
BCRX's Equity to Asset is ranked higher than
70% of the 937 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. BCRX: 0.61 )
BCRX' s 10-Year Equity to Asset Range
Min: -0.23   Max: 0.98
Current: 0.61

-0.23
0.98
F-Score: 4
Z-Score: 4.91
M-Score: -2.54
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -197.28
BCRX's Operating margin (%) is ranked higher than
66% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: -75.73 vs. BCRX: -197.28 )
BCRX' s 10-Year Operating margin (%) Range
Min: -17879.61   Max: -18.42
Current: -197.28

-17879.61
-18.42
Net-margin (%) -207.94
BCRX's Net-margin (%) is ranked higher than
66% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: -78.15 vs. BCRX: -207.94 )
BCRX' s 10-Year Net-margin (%) Range
Min: -17170.39   Max: -18.03
Current: -207.94

-17170.39
-18.03
ROE (%) -114.48
BCRX's ROE (%) is ranked higher than
57% of the 1147 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. BCRX: -114.48 )
BCRX' s 10-Year ROE (%) Range
Min: -544.61   Max: -8.43
Current: -114.48

-544.61
-8.43
ROA (%) -45.87
BCRX's ROA (%) is ranked higher than
66% of the 1253 Companies
in the Global Biotechnology industry.

( Industry Median: -27.49 vs. BCRX: -45.87 )
BCRX' s 10-Year ROA (%) Range
Min: -67.46   Max: -7.68
Current: -45.87

-67.46
-7.68
ROC (Joel Greenblatt) (%) -13674.69
BCRX's ROC (Joel Greenblatt) (%) is ranked higher than
53% of the 1227 Companies
in the Global Biotechnology industry.

( Industry Median: -437.61 vs. BCRX: -13674.69 )
BCRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -6910.46   Max: -43.48
Current: -13674.69

-6910.46
-43.48
Revenue Growth (3Y)(%) -39.50
BCRX's Revenue Growth (3Y)(%) is ranked higher than
62% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. BCRX: -39.50 )
BCRX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 430.1
Current: -39.5

0
430.1
EBITDA Growth (3Y)(%) -14.10
BCRX's EBITDA Growth (3Y)(%) is ranked higher than
70% of the 714 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. BCRX: -14.10 )
BCRX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -41.9   Max: 64.5
Current: -14.1

-41.9
64.5
EPS Growth (3Y)(%) -10.20
BCRX's EPS Growth (3Y)(%) is ranked higher than
74% of the 729 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. BCRX: -10.20 )
BCRX' s 10-Year EPS Growth (3Y)(%) Range
Min: -38.4   Max: 52.9
Current: -10.2

-38.4
52.9
» BCRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2012

BCRX Guru Trades in Q3 2012

Jim Simons 70,129 sh (-52.93%)
» More
Q4 2012

BCRX Guru Trades in Q4 2012

Jim Simons Sold Out
» More
Q1 2014

BCRX Guru Trades in Q1 2014

Jim Simons 90,514 sh (New)
George Soros 59,700 sh (New)
» More
Q2 2014

BCRX Guru Trades in Q2 2014

George Soros Sold Out
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with BCRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-06-30 Sold Out 0.01%$7.37 - $12.52 $ 11.8322%0
George Soros 2014-03-31 New Buy0.01%$7.6 - $12.83 $ 11.8312%59700
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 10.20
BCRX's P/B is ranked higher than
66% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 6.25 vs. BCRX: 10.20 )
BCRX' s 10-Year P/B Range
Min: 1.04   Max: 122.5
Current: 10.2

1.04
122.5
P/S 38.20
BCRX's P/S is ranked higher than
72% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 28.14 vs. BCRX: 38.20 )
BCRX' s 10-Year P/S Range
Min: 0.73   Max: 2000
Current: 38.2

0.73
2000
EV-to-EBIT -20.38
BCRX's EV-to-EBIT is ranked higher than
84% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. BCRX: -20.38 )
BCRX' s 10-Year EV-to-EBIT Range
Min: -41.9   Max: 0.7
Current: -20.38

-41.9
0.7
Current Ratio 2.71
BCRX's Current Ratio is ranked higher than
64% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. BCRX: 2.71 )
BCRX' s 10-Year Current Ratio Range
Min: 2.01   Max: 39.53
Current: 2.71

2.01
39.53
Quick Ratio 2.71
BCRX's Quick Ratio is ranked higher than
66% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. BCRX: 2.71 )
BCRX' s 10-Year Quick Ratio Range
Min: 2   Max: 39.53
Current: 2.71

2
39.53

Valuation & Return

vs
industry
vs
history
Price/Net Cash 11.60
BCRX's Price/Net Cash is ranked higher than
82% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 53.79 vs. BCRX: 11.60 )
BCRX' s 10-Year Price/Net Cash Range
Min: 0.61   Max: 315
Current: 11.6

0.61
315
Price/Net Current Asset Value 11.20
BCRX's Price/Net Current Asset Value is ranked higher than
81% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 31.40 vs. BCRX: 11.20 )
BCRX' s 10-Year Price/Net Current Asset Value Range
Min: 0.61   Max: 191
Current: 11.2

0.61
191
Price/Tangible Book 10.20
BCRX's Price/Tangible Book is ranked higher than
72% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9.45 vs. BCRX: 10.20 )
BCRX' s 10-Year Price/Tangible Book Range
Min: 0.33   Max: 121.33
Current: 10.2

0.33
121.33
Price/Median PS Value 5.20
BCRX's Price/Median PS Value is ranked higher than
69% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. BCRX: 5.20 )
BCRX' s 10-Year Price/Median PS Value Range
Min: 0.13   Max: 139.71
Current: 5.2

0.13
139.71
Earnings Yield (Greenblatt) -4.90
BCRX's Earnings Yield (Greenblatt) is ranked higher than
75% of the 1221 Companies
in the Global Biotechnology industry.

( Industry Median: -6.20 vs. BCRX: -4.90 )
BCRX' s 10-Year Earnings Yield (Greenblatt) Range
Min: -4.9   Max: 1563.9
Current: -4.9

-4.9
1563.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:BO1.Germany,
Biocryst Pharmaceuticals Inc. is a Delaware corporation originally founded in 1986. The Company is engaged in the design, optimization and development of novel drugs that block key enzymes involved in the pathogenesis of diseases. It integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. It uses X-ray crystallography, computer modeling of molecular structures and advanced chemistry techniques on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. The Company's drug candidates include Peramivir, BCX4161, Two 2nd generation HAE compounds, BCX4430, Forodesine and Ulodesine. Peramivir is a neuraminidase inhibitor for the treatment of patients with influenza and a potent, intravenously administered antiviral agent that rapidly delivers high plasma concentrations to the sites of infection. BCX4161 is a novel, selective inhibitor of plasma kallikrein in development as an orally-administered treatment for the prevention of attacks in patients with Hereditary Angioedema. Forodesine is a PNP inhibitor in development as a treatment for cancer. Ulodesine is a PNP inhibitor developed as a once-daily oral, chronic treatment for gout. The Company's product candidates are subject to extensive and rigorous domestic government regulations prior to commercialization.
» More Articles for BCRX

Headlines

Articles On GuruFocus.com
comment on BCRX Mar 02 2013 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 15 2011 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-K/A) Jan 19 2011 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 08 2010 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 06 2010 
BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 2,500 Shares Aug 06 2010 
BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 1,250 Shares Jun 04 2010 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) May 07 2010 
BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 1,250 Shares May 05 2010 
BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 38,553 Shares Apr 30 2010 

More From Other Websites
5:46 am BioCryst Pharm announced that the FDA has granted orphan drug designation to BCX4161 for the... Dec 24 2014
BioCryst Receives Orphan Drug Designation for BCX4161 for the Treatment of Hereditary Angioedema Dec 23 2014
BioCryst Receives Orphan Drug Designation for BCX4161 for the Treatment of Hereditary Angioedema Dec 23 2014
BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers Dec 23 2014
BioCryst Announces Study Results for BCX4430 in a Non-Human Primate Model of Ebola Virus Infection Dec 23 2014
BioCryst Announces Study Results for BCX4430 in a Non-Human Primate Model of Ebola Virus Infection Dec 23 2014
From penny-stock fears to first-of-kind flu treatment: The story of Rapivab Dec 22 2014
FDA approves BioCryst's intravenous flu drug Dec 22 2014
BioCryst gets FDA approval for flu drug Rapivab Dec 22 2014
BioCryst gets FDA approval for flu drug Rapivab Dec 22 2014
BioCryst says FDA approves oral flu drug Rapivab Dec 22 2014
BioCryst says FDA approves oral flu drug Rapivab Dec 22 2014
BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 22 2014
FDA approves BioCryst's flu shot Dec 22 2014
BioCryst's RAPIVAB(TM) (peramivir injection) Receives FDA Approval for the Treatment of Acute... Dec 22 2014
BioCryst's RAPIVAB(TM) (peramivir injection) Receives FDA Approval for the Treatment of Acute... Dec 22 2014
BioCryst Initiates OPuS-2: A Clinical Trial of BCX4161 in Patients With Hereditary Angioedema Dec 18 2014
BioCryst Initiates OPuS-2: A Clinical Trial of BCX4161 in Patients With Hereditary Angioedema Dec 18 2014
BioCryst Announces Initiation of a Phase 1 Clinical Trial of BCX4430 for the Treatment of... Dec 15 2014
It Could be a Big December for Biotech ETFs Dec 04 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK